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ABSTRACT: Understanding the mechanisms of drug resistance in
Plasmodium vivax, the parasite that causes the most widespread form of
human malaria, is complicated by the lack of a suitable long-term cell culture
system for this parasite. In contrast to P. falciparum, which can be more
readily manipulated in the laboratory, insights about parasite biology need to
be inferred from human studies. Here we analyze the genomes of parasites
within 10 human P. vivax infections from the Peruvian Amazon. Using next-
generation sequencing we show that some P. vivax infections analyzed from
the region are likely polyclonal. Despite their polyclonality we observe
limited parasite genetic diversity by showing that three or fewer haplotypes
comprise 94% of the examined genomes, suggesting the recent introduction of parasites into this geographic region. In contrast
we find more than three haplotypes in putative drug-resistance genes, including the gene encoding dihydrofolate reductase-
thymidylate synthase and the P. vivax multidrug resistance associated transporter, suggesting that resistance mutations have
arisen independently. Additionally, several drug-resistance genes are located in genomic regions with evidence of increased copy
number. Our data suggest that whole genome sequencing of malaria parasites from patients may provide more insight about the
evolution of drug resistance than genetic linkage or association studies, especially in geographical regions with limited parasite
genetic diversity.
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■ BACKGROUND
At present there is still no long-term sustainable culture system
for Plasmodium vivax, the parasite responsible for 47% of
malaria outside of sub-Saharan Africa.1 P. vivax malaria, which
can be fatal and is endemic in 57 countries,1 is primarily treated
with chemotherapy. Chloroquine plus primaquine is used in
many areas of the world, such as South America, where
resistance is not widespread,2 while artemisinin-based combi-
nation therapies (ACTs) are used in high-transmission areas,
such as Papua New Guinea, where chloroquine-resistant P.
vivax has been observed.3 Antifolates, such as the sulfadoxine-
pyrimethamine combination (Fansidar), are not recommended
for use because of widespread parasite resistance but have been
used extensively in the past. Pyrimethamine was added to table
salt in some countries, including Brazil in the 1950s.4,5
Although P. vivax alleles conferring resistance to pyrimeth-
amine are well known6−9 and are found in the Amazon basin,
alleles conferring resistance to chloroquine, artemisinin, and
primaquine (the only therapy that prevents vivax malaria
relapse) in P. vivax remain obscure.
To improve surveillance for drug resistance and to prevent
complications from treatment with inadequate therapies it
would be desirable to identify molecular markers of drug
resistance. However, the lack of long-term culture methods for
P. vivax complicates the identification of resistance genes using
in vitro evolution or genetic crosses. On the other hand, given
that there is no shortage of patients with P. vivax malaria,
population genetic studies may provide an attractive method
for mapping genes involved in drug resistance. In fact genome-
wide association studies were recently used to identify loci
involved in P. falciparum artemisinin resistance.10−13 Although
population-based approaches are theoretically possible with P.
vivax, to utilize these techniques it would be desirable to
understand the frequency of polyclonal infections, levels of
population structure, and rates of parasite inbreeding in
different locations as this can affect the design of population-
based studies.
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Although researchers have sought to address such questions
about P. vivax populations using microsatellite markers and P.
vivax DNA derived from patient infections, microsatellite
markers are genetically less stable than single nucleotide
variants (SNVs) and may provide overestimates of genetic
diversity. Conversely, reliance on too few microsatellite markers
may underestimate diversity, especially in closely related
parasites.14 Here we use next-generation sequencing (NGS)
to analyze the genomes of P. vivax parasites collected from
patients in an isolated mining camp in Peru, a country that has
experienced a resurgence in malaria cases over the last half a
century following near elimination.15,16 Even with a small
sample size we find evidence of intrainfection polyclonality,
interinfection clonality, and inbreeding, all factors that could
affect sample size calculations in genetic mapping studies.
Despite a relatively homogeneous population, we nevertheless
find evidence of recent evolution in known drug-resistance
genes, indicating that the direct examination of genome
sequences and candidate drug-resistance genes may provide
insight into the genetic basis of drug resistance in this parasite.
■ RESULTS AND DISCUSSION
Whole Genome Sequencing Identifies Polyclonality in
the Madre de Dios Region. To investigate parasite genetic
diversity and clonality in the Peruvian Amazon, 10 human
whole blood samples (Mdio01, Mdio03−11) were collected
from P. vivax-infected patients presenting to a local health post
in the Madre de Dios region of Southeastern Peru (Table S1).
Blood was drawn from patients and filtered with CF11 cellulose
powder (Whatman) to remove human white cells before DNA
isolation. Microsatellite analysis was first performed at five
markers to establish a baseline understanding of the clonality
for each sample (Table 1), and then whole genome sequencing
was performed to further investigate the composition of the
samples. Illumina paired-end sequencing yielded a mean
coverage of 10.7× per sample with an average of 29.2% of
the reads aligning to the P. vivax Sal1 reference genome.
Because of the poor coverage in four of the samples, they were
not included in further whole genome analysis. The six samples
(Mdio03, 05, 06, 08, 10, and 11) used for subsequent analysis
had a mean coverage of 16.6× (Table 2).
All 10 samples were used for microsatellite analysis, and 4 of
these samples (Mdio04, 6, 8, and 9) had multiple microsatellite
repeat sizes suggesting preliminary evidence of polyclonality in
these infections (Table 1). Polyclonal infections could arise
from mosquito injection of sibling parasites derived from a
single meiosis into a person, from “superinfection” from
multiple infectious mosquito bites, with each delivering
subsequent genetically unrelated parasites, or from a combina-
tion of a relapse and a new infection. To gain further insight
into the cause of polyclonality in these samples we genotyped
each strain at 14 651 polymorphic sites that were confidently
called in all samples (Methods, Table S2). Of these, a mean of
11 665 sites were polymorphic per sample (Table 3).
Within a given sample, many polymorphic sites had mapped
reads bearing two different alleles (mixed reads, designated the
major and minor alleles based on read frequency), suggesting
that the infection consisted of more than one parasite clone.
The NGS data showed that all samples carried mixed-allele
polymorphisms, ranging from 6% of genotyped sites in Mdio3
to 28% of the sites in Mdio10, compared to the microsatellite
data, which showed that only two of the six high-coverage
samples were polyclonal. We additionally calculated the within-
host diversity metric, Fws,
17,18 an indicator of the multiplicity of
infection (MOI) that considers the relative proportions of
clones within a sample as well as the genetic divergence of the
sample from the local parasite population. This metric is more
robust to locus-specific artifacts that may occur using
microsatellite analysis to calculate MOI. The Fws for the
Madre de Dios isolates was between 0.46 and 0.83 (Table 3),
where values ≤0.7 are considered highly diverse. We previously
observed Fws metrics between 0.97 and 0.94 for monoclonal P.
vivax relapse infections.14 Thus, these data suggest that the
Madre de Dios infections may be polyclonal, particularly
Mdio10, which has the lowest Fws and the greatest number of
polymorphic sites in the genotyped set.
Madre de Dios P. vivax Genomes Are Composed of
DNA from Three Hypothetical Haplotypes. Previous
population studies of P. vivax, specifically those in the Peruvian
Amazon, have revealed substantial genetic diversity among
parasite populations with the vast majority of every infection
examined appearing to be composed of a different haplotype
using tandem repeat polymorphic markers.19−21 Indeed our
Table 1. Microsatellite Repeat Size for Five Markers (bp)a
microsatellite marker
sample collection date 14.185 4.2771 6.34 12.335 7.67
Mdio01 May 09, 2012 283 85 160 170 101
Mdio03 April 21, 2012 286 80 160 164 103
Mdio04 April 26, 2012 283 85/96 160 162 101
Mdio05 April 21, 2012 270 85 160 170 101
Mdio06 May 11, 2012 283 85/98 158 160 101
Mdio07 April 23, 2012 286 98 162 N/A 101
Mdio08 May 02, 2012 283 85/98 160 160 103
Mdio09 May 14, 2012 283 80/95 134 170 99
Mdio10 May 07, 2012 270 85 158 162 101
Mdio11 April 19 2012 283 85 134 170 103
aAlleles for each microsatellite loci are reported as PCR product size.
Three to four unique genotypes are identified at each marker. All
haplotypes observed are unique and nonoverlapping. bp, base pairs;
N/A, not available.
Table 2. Whole-Genome Resequencing Statistics for 10




















Mdio01 22.1 6.35 25.7 6.8 4.7
Mdio03 18.5 8.23 19.9 50 24
Mdio04 13.8 4.24 20.4 9.3 1.5
Mdio05 14.2 22.3 49.0 76 65
Mdio06 14.7 28.1 55.4 78 70
Mdio07 13.3 4.23 20.7 9.4 1.3
Mdio08 13.5 10.6 30.3 62 36
Mdio09 6.72 1.74 18.3 1.0 0.5
Mdio10 11.5 16.1 43.5 73 57
Mdio11 38.0 14.4 21.7 62 35
average 15.8 10.7 29.2 39 27
aFour samples (Mdio01, Mdio04, Mdio07, and Mdio09) were
excluded from genotyping studies because the P. vivax read coverage
was low. This is most likely due to high levels of contaminating human
DNA or in the case of Mdio01, contamination with P. falciparum
DNA.
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microsatellite analysis using just four markers (excluding 4.2771
which was polyclonal) showed a unique haplotype for each of
the samples tested in our small population. Because the
transmission of malaria in Madre de Dios is not expected to be
high, we would expect the parasites genotyped here to be more
closely related. Therefore, we assessed the relatedness of the
parasites comprising each infection. Principle component
analysis (PCA) using the 14 651 genotyped sites showed that
the Mdio06 and Mdio08 infections were nearly identical
(Figure 1A). Furthermore, although Mdio05 and Mdio10 are
somewhat unrelated when considering all alleles, they are nearly
indistinguishable if polyclonal sites are excluded (Figure 1B) or
if only the major allele is considered for the PCA (Figure 1C).
The data suggest the clones present at the highest frequency in
the Mdio05 and 10 infections are nearly identical but that the
minor allele clones are different. When comparing the Madre
Table 3. Genotyping Summarya
strain Mdio03 Mdio05 Mdio06 Mdio08 Mdio10 Mdio11
genotyped 32 199 32 199 32 199 32 199 32 199 32 199
SNVs covered >5 reads for major allele 21 139 30 915 31 424 25 487 29 887 26 041
SNVs passing filtering criteria with unmapped contigs 15 380 15 380 15 380 15 380 15 380 15 380
genotyped sites mapping to 14 chromosomes 14 651 14 651 14 651 14 651 14 651 14 651
polymorphic sites
single allele SNVs 8494 10 989 11 240 11 023 8868 9360
mixed allele SNVs 1016 1119 1141 1319 4132 1286
Fws 0.770 0.827 0.818 0.829 0.464 0.781
SNVs in coding regionsb
nonsynonymous 2465 3272 3360 3274 2617 2371
synonymous 1718 1952 2298 2264 1830 1718
unique SNVs 7 2 3 1 1 0
aSingle-nucleotide variants (SNVs) were called in the six samples with the highest mean read coverage. There were 14 651 sites in all 6 samples
where a definitive base call could be made and mapped to one of the 14 chromosomal contigs. bMixed-allele sites are excluded from the analysis.
Figure 1. Principal component analysis of P. vivax genome sequences. (A) PCA of Madre de Dios genome sequences with all alleles in polyclonal
sites included (14 651 sites). (B) PCA of genotypes excluding polyclonal sites (9499 sites). (C) PCA of major alleles with polyclonal sites included
(14 651 sites). (D) PCA of Madre de Dios samples combined with worldwide isolates.14,22,23 EAC01, 02, 03 are from East Africa. Data is from the
short read sequence archive, EAC01/03 SRA057904; North Korea I, SRP000316; Mauritania I, SRP000493; Brazil I, SRP007883; India VII,
SRP007923; and IQ07, SRP003406.
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de Dios population with other global P. vivax isolates (from
Brazil, India, North Korea, Mauritania,22 Peru,23 and East
Africa14), PCA showed that all six Madre de Dios samples were
very closely related, even when considering Brazil I and IQ07,
both P. vivax isolates from the Amazon basin (Figure 1D).
Given the similarity of the population as a whole, we further
sought to determine if the parasites would share chromosomal
regions containing identical alleles, interspersed with unrelated
regions, suggestive of sexual recombination. We performed
pairwise comparisons of allele composition along each
chromosome using the set of 9499 SNVs with no minor allele
(Figure 2A). These data supported the PCA clustering data
showing that Mdio06 and Mdio08 and Mdio05 and Mdio10
were closely related. Additionally, of the 5071 sites that were
identical within the set of 6 sequences (and the nonancestral
allele), most were spatially clustered along the chromosomes,
indicating linkage. For example, Mdio03, 05, 10, and 11 are
virtually identical to one another on chromosome 1: Mdio10
and Mdio11 differ at only 10 of 449 genotyped sites in contrast
to Mdio08 and Mdio11, which differ at 231 of the 449 sites. In
contrast, Mdio08 shares the same haplotype with Mdio06,
Mdio05, and Mdio11 in parts of chromosomes 4 and 6.
The data also show evidence of meiotic recombination
among the haplotypes as was previously shown.14 To determine
Figure 2. Similarity of the Madre de Dios isolates over the entire genome. (A) Pairwise comparisons showing regions of identity and the difference
between isolates Mdio03, 05, 06, 10, and 11 compared to Mdio08 were conducted using the 9499 sites where no second allele was observed. Light
colors represent the conservation of sequence; dark shading represents mismatches. (B) Number of haplotypes calculated for each region of the
chromosome assessed by calculating a pairwise distance matrix for 50 000 kb overlapping windows.
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the number of founding parasites that may have contributed to
the Madre de Dios breeding populations, we examined blocks
of co-inherited markers (Methods). We found that 8.2 million
bases (26% of the genome) were in regions that were identical
across all isolates (a single haplotype). On the other hand, 43
and 25% of the genome (Figure 2B) were composed of two
and three haplotypes, respectively. The remaining 6% of the
genome contained four or five haplotypes. Six haplotypes (the
maximum number that can be observed) were never observed.
The isolated regions with more than three haplotypes typically
spanned likely recombination junctions, were in regions
containing known polymorphic genes, or were in genomic
regions bearing signatures of a possible genome amplification
event (see below). For instance, of the 10 allelic differences
between Mdio10 and Mdio11 on chromosome 1, 3 are in a
polymorphic gene (PVX_093645, bp 717 749 to 728 479) that
contains 12 coding and noncoding substitutions. Mdio03 had
the most SNVs that were present in only one strain (unique
SNVs, Table 3), and it had only seven. These data suggest that
two to three parasites contributed to a recombining parasite
population in Madre de Dios and that differences observed
within these parental genotypes are due to intrinsic mutation
rates.
Exploration of Orthologs of Known Drug-Resistance
Genes and Identification of Potential Novel Resistance-
Associated Genes. We also examined orthologs of known
drug-resistance genes in P. falciparum to determine if any of
these genes in P. vivax showed evidence of selection. All P.
vivax malaria patients are currently treated with primaquine and
chloroquine in Peru (CQ 25 mg/kg, PQ 0.5 mg/kg for 7
days),24 although chloroquine resistance is found in the
Amazon region and contributes to treatment failure in some
countries.25−27 The genes involved in chloroquine resistance in
P. vivax are unknown, but good candidates include the
orthologs of the P. falciparum genes that are involved in
resistance, the chloroquine resistance transporter (pvcrt-o,
PVX_087980), and the multidrug resistance transporter
(pvmdr1, PVX_080100) (Table 4). Pvmdr1 (T958M) bore a
single variant relative to the SalI reference sequence; this same
allele change has arisen, presumably independently in Thai-
land28 and in Madagascar.29 We found no coding changes in
pvcrt-o, although no exonic coding changes in pvcrt-o have been
observed even in parasites resistant to chloroquine.29 Never-
theless, we did find six intronic changes and one mutation in 5′
UTR, placing it in the top 1% of genes with intronic changes
(Table 4). Interestingly, increased expression of pvcrt-o in
Table 4. Coding Changes Relative to the SalI Reference Sequence for Known Drug-Resistance Genesa
Chr Pos. AA ref 03 05 06 08 10 11 Br IQ07 IndVII Mau NK
P. vivax Bifunctional Dihydrofolate Reductase-Thymidylate Synthase (pvdhf r, PVX_089950)
5 964763 S58R C A A G G A A A G G C C
5 964796 Y69 T C C C C C C C C T T T
5 964856 G89 T T/G T/G T/G T/G T T G G G G G
5 964939 S117N G A A A A A A A A A G G
5 965106 I173L A A C A A C/A A C A A A A
5 966035 E482D A A/T A A A A A A A A A A
5 966144 L519 C C C C C C C A A A A A
P. vivax Multidrug Resistance Gene 1 (pvmdr1, PVX_080100)
10 363223 T958M G A A A A A A A A A A A
P. vivax Multidrug Resistance Associated Protein 1 (pvmrp1, PVX_124085)
14 2043012 S1689L G A/G G/A G G G G G G G G G
14 2043021 T1686K G T G/T G/T G G G/T G G G G G
14 2043859 Q1407E G C C C C C G C G C C C
14 2044798 A1094S C C A A A A C A C C C C
14 2045050 V1010M C T T T T T T T T T T T
14 2046126 V651G A A A A/C A C/A A A A A A A
14 2046219 R620Q C C T C C T C C C C C C
14 2047233 R282M C A A A A A A A A A A A
14 2047816 E88Q C G G C C G C C G C G C
Chloroquine Resistance Transporter Ortholog (pvcrt-o, PVX_087980)
1 330262 5′ UTR T C C C C C C T T Y C C
1 331151 intron T C C C C C C C C C C C
1 331819 intron G G G A A G G G G G G G
1 332453 intron T C C C C C C C C C C C
1 332874 intron A C C C C C C C C C C C
1 333469 intron G G/A G G/A G/A G G G G G G G
1 333473 intron G G G G/T G/T T T G G G G G
1 333518 intron A G G A A G G A G G G A
1 333544 intron T C C C C C C T C C C T
1 334324 intron A A/T A T A/T A/T A/T A A T A A
aMutations in Madre de Dios isolates identified in the 14 651 confidently called set and mutations identified in Brazil I (Br), India VII (IndVII),
Mauritania I (Mau), and North Korea (NK) isolates identified from plasmodb.com were included. No single-nucleotide variants leading to coding
changes were observed for cytochrome bc1 (NC_007243), dihydropteroate synthetase (PVX_123230), gtp cyclohydrolase (PVX_123830),
chloroquine resistance transporter ortholog (PVX_087980), or kelch 13 (PVX_083080) orthologue. Y, pyrimidine.
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chloroquine-resistant parasites from the Amazon has been
observed.30
Furthermore, we found no amino acid changes in the
mitochondrially encoded gene, plviomp3, which encodes the
cytochrome bc1 complex, the target of atovaquone in P.
falciparum.31 We also found no nonsynonymous mutations
relative to SalI in pvkelch13 (PVX_083080), the P. vivax
ortholog of pfkelch13,10 a gene conferring reduced sensitivity to
artemisinin in P. falciparum (reviewed in ref 32) presumably
because ACTs are not currently used in the Amazon region.
A number of coding changes were observed in the P. vivax
multidrug resistance associated protein (pvmrp1 ,
PVX_124085), which bore nine nonsynonymous SNVs and
two synonymous SNVs (Table 4). Position 1466K variants are
associated with antifolate resistance in P. falciparum,33 and the
disruption of this gene in P. falciparum leads to increased
primaquine sensitivity.34 Pvmrp1 was previously noted because
of an unexpectedly high number of coding variants observed in
another South American P. vivax patient isolate.23 A homology
model using the Caenorhabditis elegans multidrug resistance
protein, PGP-1,35 shows several of the mutations observed in
the Madre de Dios population occurring in structurally
conserved regions of the protein including the nucleic acid
binding domain in the intracellular space (Figure 3).
Although antifolates are no longer recommended in Peru we
found that coding mutations in the antifolate pathway were
common, with all isolates carrying the S117N and S58R
dihydrofolate reductase (dhfr) mutations, known in combina-
tion to confer high levels of resistance to pyrimethamine in P.
vivax (Table 4).8,36 Notably, we found two independent S58R
nucleotide transversions (C → A, C → G). Triallelic mutations
are a feature shared by only 19 other genes, including the apical
merozoite antigen (ama-1; PVX_092275) (Table S3), suggest-
ing selection pressure on this nucleotide position. A subset
(Mdio05 and Mdio10) also carried the I173L allele associated
with treatment failure.36 Given how different these strains are
from those in other countries (Figure 1D), it is expected that
these mutations arose independently and were not imported.
We found there were no novel variants in dihydropteroate
synthetase (dhps; PVX_123230) or GTP cyclohydrolase (gtpch;
PVX_123830), other genes in the dihydrofolate biosynthesis
pathway.
It has been shown, on the basis of mapping study experiences
with chloroquine- and pyrimethamine-resistant P. falciparum
field isolates, that patterns of linkage for disequilibrium could
be used to detect genes conferring drug resistance.37,38 These
studies have indicated that genes involved in antifolate and
chloroquine resistance have arisen infrequently and have likely
been transmitted through populations by selective sweeps.37,38
In contrast to what was observed for P. falciparum, the region
around dhfr on chromosome 5 (pvdhf r, bp 964 590 to 966 464)
did not show strong evidence of linkage disequilibrium within
the Madre de Dios parasite genomes (an 80 kb surrounding
region showing two haplotypes is displayed in Figure 4),
suggesting that mutant pvdhf r has arisen more than once.
Evolution of Other Genes. To further identify genes
under selection and potential genes not known to be involved
in drug resistance we identified genes with a high non-
synonymous substitution to synonymous substitution ratio
(Ka/Ks). Of the top 20 genes with high Ka/Ks, 18 are
hypothetical, reflecting the lack of information about the
interaction of P. vivax with the human immune system. Those
genes with functional annotations typically played possible roles
in immune evasion, including members of the msp3 multigene
family (Table S4), as well as PVX_092625 which encodes an
uncharacterized protein, the ortholog of a possible P. falciparum
vaccine candidate, predicted to be surface expressed.39 No
statistically significant Ka/Ks ratios were observed for orthologs
of known P. falciparum drug-resistance genes (Table S5). The
majority of genes (3773 out of 5507 queried), on the other
hand, had no nonsynonymous variants in any of the isolates,
reflecting the overall lack of diversity in the population.
Genome Regions around pvmrp1 and Genes of the
Folate Biosynthetic Pathway Show Evidence of Gene
Amplification. Changes in the gene copy number have been
shown to or are predicted to confer drug resistance in
laboratory-evolved P. falciparum clones40 and P. falciparum field
isolates41 and are relatively common. We thus looked for
Figure 3. Homology model of PvMRP1 using C. elegans PGP-1 as a template. This ABC transporter protein is located in the parasite plasma
membrane and has two nucleotide binding domains (NBDs) conserved between the two proteins. The locations of SNVs identified in NBD1 and
NBD2 are shown in the insets. SNVs identified but not shown are in transmembrane domains.
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potential increased read coverage across the genome in the
Madre de Dios P. vivax sequences using an automated CNV-
calling algorithm.42 On average, 2.8% of the genome was
potentially amplified and 1.5% showed evidence of a deletion
event (Figure 5A). Deleted regions typically encoded members
of multigene families. For example, a 100 kb region on
chromosome 12 encodes members of the PfamD family, early
transcribed membrane proteins, and exported proteins. An
∼200 kb region on chromosome 3 was deleted in Mdio5,
Mdio6, and Mdio10 and encoded ∼15 VIR proteins, 7
plasmodium exported proteins, a PfamD family protein
member, and an early transcribed member protein as well as
“hypothetical” proteins.
In contrast to what is found in P. falciparum43,44 and P. vivax
in Thailand45 we found little evidence of increased read
coverage near pvmdr1 on chromosome 10 (361 701−366 095)
nor could we find evidence of an amplification event near pvcrt-
o (chr1:330 260 to 334 540). On the other hand, the region
around pvmrp1 (chr14:2 042 042−2 048 077) in Mdio06,
Mdio08, and Mdio05 has increased read coverage suggestive
of a copy number variant in that region (Figure 5B). Although
amplification of this gene in P. vivax or P. falciparum patient
isolates have not been reported, P. falciparum parasites exposed
to atovaquone in the laboratory also acquired a CNV that
encompassed this gene,46 providing some evidence that extra
copies provide an adaptive advantage.
Our data showed that pvdhf r is contained within a region
with significantly increased read coverage in Mdio08 (Figure
5C), and manual inspection also showed increased read
coverage in Mdio06. In addition, we also found that four
isolates had significantly increased read coverage around the P.
vivax dihydrofolate synthase gene (pvdhfs; PVX_116635),
which encodes the protein upstream of dihydrofolate reductase
in the folate biosynthesis pathway and converts 7,8-
dihydropteroate, and L-glutamate to 7,8-dihydrofolate through
the hydrolysis of ATP. Recombination events surrounding
smaller amplified regions (e.g., 2 kb) were conclusively
observed upstream and downstream of pvdhf r, suggesting that
the genome may have harbored a large 30−40 kb amplification
at one time, but the amplified region may have been partially
Figure 4. Chromosome 5 alleles surrounding P. vivax dhf r. Genotyped sites with no minor alleles in the Madre de Dios set were used to avoid
possible phasing errors. Positions in bold are dhf r. Red and green alternate shading denote open reading frames. Blue, orange, and purple shading
indicate identical haplotypes in this 80 kb region on chromosome 5.
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lost as antifolate drug pressure was removed. Sequencing to a
higher depth of coverage or the use of long read sequencing
technology such as PacBio could provide more resolution.
Further evidence for pvdhfs amplification as well as dhf r SNVs
is suggestive of selective pressure from the past indiscriminate
use of antifolates in the 1950s and 1960s.4,5
Amplified regions with no clearly known drug-resistance
genes were also observed (Table S6) and could represent novel
resistance markers. Examples of such amplified regions include
chromosome 1:473 919−541 139 bp and a number of regions
on chromosome 3 that were observed in all but Mdio03.
Although sequencing coverage is too low to establish exact
boundaries of these events, one possibly interesting gene that
Figure 5. Copy number variants identified in Madre de Dios isolates using a systematic calling algorithm. (A) Distribution of increased (red) and
decreased (blue) read coverage in all isolates. Sensitivity is based on overall read coverage for an isolate, and regions may have been missed in isolates
with overall lower sequencing depth (e.g., Mdio03). (B) Normalized coverage depth and predicted copy number for Mdio06 chromosome 14
showing the amplification of pvmrp1. (C) Normalized coverage depth and predicted copy number for Mdio08 chromosome 5, highlighting
amplification in pvdhf r.
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was potentially amplified in this region is PVX_000585, which
is predicted to encode a homologue of the E. coli multidrug
transporter, EmrE. This membrane protein exchanges small
aromatic drugs such as ethidium bromide and methyl viologen
(paraquat) across the membrane in E. coli47 and belongs to the
same transporter class as pfcrt.48 Orthologs are missing from
most eukaryotes but are found in other apicomplexan parasites
such as Toxoplasma gondii and Babesia bovis (OrthoMCL DB
v.5.0). Further work will be needed to establish whether these
changes are significant.
■ CONCLUSIONS
Our data highlight potential challenges with using genetic
mapping methods to identify genes involved in antimalarial
drug resistance. These include inbred populations, which can
skew the true diversity of the population if diversity is measured
by only a few markers; polyclonal infections, which can affect
SNV calling and haplotype inference; and the appearance of de
novo mutations which may or may not be associated with
resistance in an otherwise homogeneous genetic background. In
addition, genome amplifications, which may or may not be
correctly mapped to their correct genome location, are likely to
be common. All of these features may impact the study design.
On the other hand, our studies demonstrate that insight into
the genetic basis of drug resistance can be gained simply by
examining the genomes of parasites using high-resolution
methods. This method was previously used to identify alleles
associated with resistance to the antibiotic clindamycin in P.
falciparum isolates from Peru49 and GTP cyclohydrolase gene
amplification events in many laboratory and field isolates. The
GTP cyclohydrolase event was hypothesized to confer
resistance to antifolate drugs because of its presence in the
folate biosynthetic pathway50,51 and was eventually shown to
help parasites survive exposure to antifolate drugs by increasing
drug flux through the pathway in the presence of mutations in
pfdhf r that cause a loss of fitness.52 In our study we identify
known and novel mutations potentially involved in drug
resistance. Relatively uncharacterized genes that could be
further tested for association with resistance to currently used
therapies (primaquine and chloroquine) include pvmrp1 as well
as PVX_000585, the P. vivax homologue of the Escherichia coli
multidrug resistance gene, EmrE.
Genes involved in resistance to small molecules are now
routinely found in P. falciparum using laboratory evolution and
whole genome sequencing.53 Identification of these genes
allows for monitoring of the emergence of drug resistance in
parasite populations. Additionally, knowledge of resistance
genes can aide in the design of novel molecules that are
effective at targeting the known target in the presence of these
known population variants. The identification of resistance
genes using laboratory evolution relies on in vitro culture
systems and would be challenging for P. vivax. On the other
hand, because parasites in a region such as Madre de Dios could
effectively be clonal, such isolated parasite populations might
offer opportunities to directly observe the effects of drug
exposure on the population. Alleles that appeared in the
population only after a new therapy was introduced might be
readily identified in an inbred parasite population such as this.
Thus, archiving parasite material before and after the
introduction of a new therapy could eventually give valuable
insight into the evolution of drug resistance in the field.
Our studies also have implications for the design of clinical
trials aiming to test novel radical cure drugs that might replace
primaquine, the only licensed drug that can eliminate dormant
P. vivax and P. ovale hypnozoites. Although initial clinical trials
might be performed with travelers or soldiers returning from
endemic regions, groups that would not be expected to be
reinfected, larger patient studies in endemic regions could be
complexif a patient returned with an infection that was
genotypically very similar to his original infection, then one
might assume that the drug candidate was not effective at
preventing relapse when in fact the patient had actually been
reinfected. Thus, estimates of the number of parasite
haplotypes circulating in a region would be needed before
trials could be effectively designed. This method would be
particularly suited for an area where transmission is low and
thus less parasite diversity is expected. In regions where
diversity is high and patients are infected with multiple strains,
it may prove more difficult to observe mutations related to drug
pressure.
■ METHODS
Sample Collection. This study was approved by the
Human Subjects Protection Program of the University of
California San Diego, the Institutional Review Board of
NAMRU-6, Lima, Peru and the Directorate of Health, Madre
de Dios, Peru. Peripheral blood samples for next-generation
sequencing were collected from patients with self-reported
fever and microscopy-confirmed P. vivax malaria. Patients
presented at the Peruvian Ministry of Health facility of Bajo
Puquiri, locally called Delta-1, in the Madre de Dios
department, Peru. This location is approximately 8 h from
the capital city of Puerto Maldonado, over difficult terrain. P.
vivax monoinfection was later confirmed by PCR as previously
described.54 Blood was collected using EDTA-containing
Vacutainer tubes. Tubes were centrifuged at 1000g to remove
plasma, and the packed red blood cells were resuspended in a
2× volume of sterile phosphate-buffered saline (1.8 mM
KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 nM KCl).
Within 1 h of collection diluted blood was filtered through
CF11 cellulose powder (Whatman) to remove white blood
cells.55 Eluted blood was pelleted by centrifugation at 1000g for
10 min and stored at −20 °C for a maximum period of 2 to 3
weeks before being shipped in batches to the NAMRU-6
laboratory in a liquid-nitrogen dry shipper.
Microsatellite Analysis. P. vivax microsatellite character-
ization was conducted using the following previously published
loci: 14.185, 12.335, 7.67, 6.34, 4.2771, and 3.35.56,57
Microsatellites were amplified with primers previously
described,56 and fluorescently labeled PCR products were
analyzed on an Applied Biosystems Prism 3130xl Avant Genetic
Analyzer (Applied Biosystems). A minimum peak height of 200
fluorescent units was used to define amplification products.
Whole Genome Sequencing. Genomic DNA was isolated
from frozen whole blood samples using a DNeasy blood and
tissue kit (Qiagen), and whole genome paired end-sequencing
libraries were created using the NEBNext DNA library prep kit
(New England Biolabs). DNA was sheared using Covaris
adaptive focused acoustics and size selected on an agarose gel.
DNA libraries were clustered and run on an Illumina
HiSeq2000 (Illumina, Inc., San Diego) according to the
manufacturer’s instructions. Base calls were made using
Consensus Assessment of Sequence and Variation v. 1.8.2
(Illumina). Sequencing reads in fastq format are available on
the National Center for Biotechnology Information’s short read
archive (PRJNA272364). Reads were aligned to the P. vivax
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SalI reference (v. 10.0) using the Burrows-Wheeler aligner with
the default options.58,59 Picard was used to remove PCR
duplicates and evaluate the sequencing quality.
Single nucleotide variants (SNVs) were called simultaneously
in the Madre de Dios set of 10 using the Genome Analysis
Toolkit Unified Genotyper tool. Variant sites within SNV
clusters (cluster window = 10, SNP cluster = 3) and with low
mapping quality (MQ < 50) were filtered out. Additionally,
variant sites with a combined depth of coverage of less than 20
reads (DP < 20) were excluded. A total of 32 199 high-quality
SNVs were identified and genotyped in each of the 10 samples.
Because we were interested in high-quality SNVs that would
allow us to determine relatedness of the strains, we further
filtered the variants. Overall read coverage was low in Mdio01,
Mdio04, Mdio07, and Mdio09; therefore, these samples were
excluded from further analysis. For the samples included,
Mdio03, Mdio05, Mdio06, Mdio08, Mdio10, and Mdio11, sites
were filtered if they did not have calleable alleles in all of these
samples or a read coverage of <5. Additional custom filtering
was designed to retain sites where we were confident of the
zygosity. Homozygous SNVs were called if >80% of the reads
were the major allele, and heterozygous SNVs were called if
50−80% of the reads represented the major allele. SNVs with
more than one alternate allele were also excluded. This resulted
in 15 380 confidently calleable sites for determining clonality
located on both contigs and chromosomes. SNVs indentified in
contigs were further removed to yield a high-quality set of
14 651 genotyped sites (Table 4).
Diversity and Relatedness Analyses. To characterize
within-host diversity we used the Fws statistic
18,55 (Fws = 1 −
(Hw/Hs), where Hw is the within-host heterozygosity and Hs is
the population-level heterozygosity), using the 14 651
genotyped sites. The principle component analysis was
performed using the Matlab (R2012b, The Mathworks)
princomp command. Calculation of the ratio of the non-
synonymous substation rate to the synonymous substitution
rate (Ka/Ks) was done using the modified Yang−Neilsen
algorithm.60 Haplotype blocks were calculated using a set of
4430 SNVs with no minor allele and which were variant in one
Madre de Dios isolate relative to the others. The number of
haplotypes present was calculated for 50 kb windows (moving
over each chromosome in 5 kb steps) by calculating the
pairwise distance matrix for all sample pairs within the window.
The pairwise distance estimate, d, was calculated as d = nd/nc,
where nd is the number of nonidentical sites and nc is the
number of sites compared. Values for the distance matrix that
were less than 5 × 10−5 were considered to be similar haplotype
blocks between samples.
Pairwise Comparisons. Pairwise comparisons were
completed using either all 15 380 genotyped sites or sites
where no minor allele was shared (9571 sites left).
Chromosome maps were made to represent whether alternate
alleles were shared between samples.
Homology Modeling. Amino acid sequences of PvMRP1
were retrieved from PlasmoDB (search ID: PVX_124085) and
were cross referenced with Uniprot. A template search was
conducted against the SWISS-MODEL template library, with
the highest scoring template being chosen for model building.
A web-based homology model was produced using the SWISS-
MODEL pipeline which operates via Promod-II and Modeler
platforms. The PyMOL Molecular Graphics System (version
1.3, 2010 Schrodinger, LLC.) was then used to display and label
the protein structure.
CNV Analysis. Plasmodium Type Uncovering Software
(Platypus)61 was used to identify regions of the genome where
a significant increase or decrease in read coverage was observed.
This software sensitively detects the largest changes in read
signal after GC bias normalization. Changes were also observed
for the various unassembled contigs (data not shown).
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Supplementary Tables 
 
Demographic Characteristic Value 
Mean age 38 years  
Sex 9M:1F 
Previous malarial history 60% 
Signs of serious infection 30% difficulty breathing 
Fever present 50% > 38.5°C 
Mean parasitemia  0.45% 
 
Table S1. Demographic characteristics of the sample population, with units separate for 
each row. 10 patients were analyzed, with mean patient age and sex as well as previous malarial 
history and current clinical correlate listed. 
 
Table S2. provided separately as excel file. 
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Gene Ref Alt AA Description 
PVX_087665  T A,C D240E/
D240 
hypothetical protein 
PVX_085790  C A/T A306E/
A306V 
Sperm-specific protein Don juan, putative 
PVX_086125  C A,T P439T/P
439S 
hypothetical protein, conserved 
PVX_086250  C A,G L116M/
L116V 
hypothetical protein, conserved 
PVX_079910  A G,T V3032E/ 
V3032A 
hypothetical protein, conserved 
PVX_080525  T C,G S736R/S
763G 
asparagine-tRNA ligase, putative 
PVX_098025  G A,C S2340N/
S2340T 
DNA-directed RNA polymerase I 190 kDa polypeptide 
PVX_097695  C G,T G668E/
G668A 
merozoite surface protein 3 alpha (MSP3a), putative 
PVX_097680  G A,T N885K/
N885 
merozoite surface protein 3 beta (MSP3b) 
PVX_091820  A C,T C1407S/
C1407G 
hypothetical protein, conserved 
PVX_092275  G A,C R112K/
R112T 
apical merozoite antigen 1 
PVX_092630  T C,G N977H/
N977D 
hypothetical protein, conserved 
PVX_123760  T A,C D2961E/
D2961 
hypothetical protein 
PVX_124070 G C,T Q2494K
/Q2494E 
WD domain, G-beta repeat domain containing protein 
PVX_003820  A C,G N813T/
N813S 
serine-repeat antigen 4 (SERA), putative 
PVX_111370  T A,G R1422W
/R1422R 
hypothetical protein 
PVX_089950 C A,G S58R/S5
8R 
bifunctional dihydrofolate reductase-thymidylate synthase 1 
PVX_005057  A C,T H313P/
H313L 
Vir gene 
Table S3.  Tri-allelic SNVs observed in the Madre de Dios population. Genes with more than 
two alleles coding for nonsynonymous changes were identified and are noted. Notes: REF, P. 




	   	  
 
Gene Function Ka/Ks P-Value SYN NON-SYN 
PVX_115420 conserved hypothetical protein 8.46 0.021 1 9 
PVX_081820 conserved hypothetical protein 4.95 0.025 2 11 
PVX_086195 conserved hypothetical protein 4.79 0.143 1 7 
PVX_097685 
merozoite surface protein 3 
(MSP3) 4.38 0.202 1 13 
PVX_118020 conserved hypothetical protein 4.25 0.162 1 8 
PVX_087140 hypothetical protein 3.88 0.216 1 5 
PVX_096325 conserved hypothetical protein 3.62 0.278 1 9 
PVX_086275 conserved hypothetical protein 3.59 0.274 1 8 
PVX_091745 conserved hypothetical protein 3.56 0.040 3 12 
PVX_084725 conserved hypothetical protein 3.35 0.082 2 18 
PVX_092625 hypothetical protein 3.26 0.419 1 7 
PVX_086135 hypothetical protein 3.13 0.416 1 7 
PVX_084175 hypothetical protein, conserved 3.10 0.436 1 9 
PVX_090240 hypothetical protein, conserved 2.90 0.232 1 9 
PVX_115350 hypothetical protein, conserved 2.89 0.217 2 9 
PVX_091085 hypothetical protein, conserved 2.88 0.357 1 4 
PVX_084360 
Tat binding protein 1(TBP-1)-
interacting protein, putative 2.83 0.399 1 6 
PVX_092265 hypothetical protein, conserved 2.79 0.419 1 8 
PVX_091530 hypothetical protein, conserved 2.73 0.625 1 5 
PVX_124090 hypothetical protein, conserved 2.69 0.425 1 9 
 
Table S4. Top 20 genes with the largest Ka/Ks ratios. Calculation of substitution rates was 
done using the modified version of the Yang-Neilsen algorithm. SYN, number of synonymous 
changes; NON-SYN, number of non-synonymous changes. 
 
Gene ID Ka/Ks P-value SYN 
NON-
SYN annotation 
PVX_080100 NA NA 0 1 
multidrug resistance protein 
(mdr1) 




PVX_124085 1.02 0.933 2 9 
multidrug resistance associated 
protein (mrp1) 




PVX_083080 0 NA 7 0 kelch protein 
 
 
Table S5. Ka/Ks ratios for P. vivax orthologs of known P. falciparum drug resistance genes. 
Calculation of substitution rates was done using the modified version of the Yang-Neilsen 
algorithm. SYN, number of synonymous changes; NON-SYN, number of non-synonymous 
changes. 
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Table S6. provided separately as excel file. 
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